Cera

KalVista Pharmaceuticals, based in Cambridge, MA, is dedicated to advancing science to empower individuals living with hereditary angioedema (HAE). Through innovative research and the development of orally delivered small molecule medicines, the company aims to transform the treatment landscape for HAE patients by addressing their unmet needs. With a team of skilled professionals and experienced scientists, KalVista is focused on elevating the standard of care for patients suffering from various diseases, starting with HAE. Their lead product, sebetralstat, represents a potential new oral treatment option designed to enhance the management of this challenging condition. Generated from the website

B-FLEXION is a private investment firm with offices in Europe and the United States, partnering with sophisticated capital to deliver exceptional value over generations and contribute positively to society. With a rich history as a biopharmaceutical company and a successful investment track-record spanning 20 years, B-FLEXION has grown to encompass a diverse portfolio of asset managers and direct holdings in transformative operating businesses.Generated from the website